Both stocks look attractively valued relative to their growth potential. There are plenty of attractive stocks on the market.

The addition of sotatercept, an activin-signaling inhibitor, to background therapy results in a lower risk for clinical worsening among adults with pulmonary arterial hypertension who were diagnosed ...

TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated ...

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...